Squarepoint
PLX icon

Squarepoint’s Protalix BioTherapeutics PLX Stock Holding History

Squarepoint’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-120,786
Closed -$309K – 4936
2025
Q1 		$309K Buy
120,786
+46,846
+63% +$112K ﹤0.01% 3720
2024
Q4 		$139K Buy
73,940
+18,522
+33% +$26.2K ﹤0.01% 4596
2024
Q3 		$56.5K Sell
55,418
-82,346
-60% -$86.6K ﹤0.01% 3969
2024
Q2 		$161K Buy
137,764
+119,949
+673% +$142K ﹤0.01% 3715
2024
Q1 		$22.4K Buy
+17,815
New +$26.6K ﹤0.01% 3921
2021
Q1 		– Sell
-22,068
Closed -$80K – 3507
2020
Q4 		$80K Sell
22,068
-22,611
-51% -$81K ﹤0.01% 2752
2020
Q3 		$173K Buy
+44,679
New +$162K ﹤0.01% 2148

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Squarepoint's PLX Position: Q2 2025 in Review

Squarepoint sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 120,786 shares — an estimated $309K sold.

Squarepoint first reported a position in PLX in Q3 2020 and held it in 7 quarters. The position peaked at $309K in Q1 2025. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

  • Squarepoint reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
  • Squarepoint sold 120,786 Protalix BioTherapeutics shares in Q2 2025, an estimated $309K.
  • Squarepoint first reported a position in Protalix BioTherapeutics in Q3 2020 and held it in 7 quarters.
  • Squarepoint's Protalix BioTherapeutics position peaked at $309K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.